劲方医药-B(02595):Rev Med发出函件所涉主体、产品、争议事项均与公司无关

智通财经
Apr 28

智通财经APP讯,劲方医药-B(02595)发布公告,公司近期注意到若干报导,涉及 Revolution Medicines Inc.(“RevMed”)向第三方公司发出有关RAS抑制剂专利及商业秘密争议的函件。

公司特此澄清并强调:Rev Med发出函件所涉主体、产品、争议事项均与公司无关,劲方Pan RAS抑制剂GFH276具备完全独立、自主原创的知识产权,不存在类似侵权或商业秘密争议风险。

劲方针对Pan RAS抑制剂项目已构建全面的全球专利布局,涵盖GFH276化合物结构的专利已于2025年3月6日正式公开,专利保护期预计可至2044年。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10